Table 1. Clinical characteristics of patients who underwent chemotherapy and immunotherapy.
| Variable | N=38 (%) |
|---|---|
| Age (medium, range) | 61 [57–75] |
| Gender | |
| Male | 36 (94.74) |
| Female | 2 (5.26) |
| BMI kg/m2 (medium, range) | 22.18 (14.3–29.76) |
| ECOG | |
| 1 | 34 (89.47) |
| 2 | 4 (10.53) |
| Smoking history | |
| Yes | 22 (57.89) |
| No | 16 (42.11) |
| Drinking history | |
| Yes | 17 (44.74) |
| No | 21 (55.26) |
| Basis disease | |
| None | 25 (65.79) |
| Hypertension | 12 (31.58) |
| Heart disease | 1 (2.63) |
| Diabetes | 2 (5.26) |
| Tumour location | |
| Proximal third | 3 (7.89) |
| Middle third | 21 (55.26) |
| Distal third | 14 (36.84) |
| Immunotherapeutic drugs | |
| Pembrolizumab | 21 (55.26) |
| Camrelizumab | 12 (31.58) |
| Sintilimab | 5 (13.16) |
| Interval from completion of NACI to surgery [weeks] | 5 [2–13] |
ECOG, eastern cooperative oncology group; NACI, neoadjuvant chemotherapy combined with immunotherapy.